ADXS News 2.67 04/28/2014 04:53:47 Advaxis Inc (ADXS)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Advaxis Inc (ADXS) 2.67 $ADXS

Advaxis to Present at 2014 American Society of Clinical Oncology Annual Meeting
GlobeNewswire - Thu Apr 24, 7:45AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced that two abstracts related to ADXS-HPV (ADXS11-001), the Company's lead immunotherapy product candidate, have been selected for poster presentation at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, May 30 - June 3, 2014, at the McCormick Place in Chicago, IL.

Japan Patent Office Issues Advaxis a Notice of Allowance for Two Patent Applications Covering Its Cancer Immunotherapy Platform Technology
GlobeNewswire - Mon Apr 14, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that the Japan Patent Office issued to Advaxis two notices of allowance for two patent applications (P-72863-JP, P-7924) with claims for each patent application related to the Company's proprietary cancer immunotherapy platform technology. These patents will provide protection in Japan until 2030.

Pending Applications, Closed Public Offering, Joint Venture Formation, Executive Appointment, and Commercial Launch - Analyst Notes on Gilead, Enzymotec, Intrexon, Advaxis, and Repligen
PR Newswire - Tue Apr 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Enzymotec Ltd. (NASDAQ: ENZY), Intrexon Corporation (NYSE: XON), Advaxis, Inc. (NASDAQ: ADXS), and Repligen Corporation (NASDAQ: RGEN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Advaxis Receives Notice of Allowance From U.S. Patent and Trademark Office for Three Patent Applications With Multiple Claims Covering Its Cancer Immunotherapy Platform Technology
GlobeNewswire - Tue Apr 01, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for three U.S. patent applications (12/213,696, 13/254,607, and 11/415,271) with claims of each application related to the Company's proprietary cancer immunotherapy platform technology. The patent with the latest date of expiry is 2030, without taking into account patent term extension.

Advaxis Announces Closing of Public Offering of Common Stock
GlobeNewswire - Mon Mar 31, 3:37PM CDT
Advaxis, Inc. (Nasdaq:ADXS) ("Advaxis" or the "Company" , today announced the closing of a previously announced underwritten public offering of 4,692,000 shares of its common stock, including the fully exercised over-allotment option by the underwriters covering 612,000 shares, offered at a price to the public of $3.00 per share. The gross proceeds to the Company were $14,076,000, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

Moskowitz: Advaxis Balance Sheet Shored Up
ACCESSWIRE - Mon Mar 31, 8:40AM CDT
Read the Advaxis Report Update: http://equitiesiq.com/reports/advaxis-update/

Advaxis Announces Full Exercise of Underwriters' Over-Allotment Option
GlobeNewswire - Fri Mar 28, 2:00PM CDT
Advaxis, Inc. (Nasdaq:ADXS) ("Advaxis" or the "Company" , today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 612,000 shares of its common stock at a public offering price of $3.00 per share in connection with its previously announced underwritten public offering of 4,080,000 shares of common stock, bring the total gross proceeds from the offering to approximately $14,076,000, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

Team Nation Holdings Corp Officially Changes its Name; Petr Shares Rise on Brazil Outlook Upgrade
ACCESSWIRE - Thu Mar 27, 11:37PM CDT
Petr (NYSE: PBR) - For an in-depth report on Petr follow: www.BullTrends.com/stockquote/PBR

Nasdaq stocks posting largest volume increases
AP - Thu Mar 27, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:

Advaxis Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Mar 26, 7:40PM CDT
Advaxis, Inc. (Nasdaq:ADXS) ("Advaxis" or the "Company" , today announced the pricing of an underwritten public offering of 4,080,000 shares of common stock at a public offering price of $3.00 per share. The Company expects to receive $12,240,000 in gross proceeds, before deducting underwriting discounts and commissions and offering expenses payable by the Company. The Company has granted the underwriters a 45-day option to purchase up to 612,000 additional shares of common stock. The Company intends to use the net proceeds from this offering to fund the Company's continued research and development initiatives in connection with expanding its product line and for other general corporate purposes.

Advaxis Announces Proposed Public Offering of Common Stock
GlobeNewswire - Wed Mar 26, 3:08PM CDT
Advaxis, Inc. (Nasdaq:ADXS) ("Advaxis" or the "Company" , today announced that it intends to offer for sale shares of its common stock in an underwritten public offering. The Company intends to use the net proceeds from this offering to fund the Company's continued research and development initiatives in connection with expanding its product line and for other general corporate purposes. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Advaxis, Inc. [ADXS] to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Wed Mar 26, 11:10AM CDT
What:

Advaxis to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Wed Mar 26, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that its management team will ring The NASDAQ Stock Market Closing Bell on Thursday, March 27, 2014.

Advaxis Appoints Sara Bonstein as Chief Financial Officer, Senior Vice President
GlobeNewswire - Mon Mar 24, 4:16PM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that it has appointed Sara Bonstein to the position of Chief Financial Officer, Senior Vice President. Ms. Bonstein has a decade of financial leadership experience in the life sciences industry with Eli Lilly & Company, ImClone Systems, and Johnson & Johnson.

Advaxis, Inc. "A Win-Win in Pet Therapeutics"
ACCESSWIRE - Fri Mar 21, 8:21AM CDT
Philadelphia, PA / ACCESSWIRE / March 21, 2014 / Advaxis, Inc. (NASDAQ: ADXS) today published a new blog post on The Chairman's Blog, written by the Company's EVP and COO, Mr. Gregory T. Mayes. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Advaxis Discusses Global Licensing Agreement for Pet Therapeutics on Conference Call
GlobeNewswire - Thu Mar 20, 11:45AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, hosted a joint conference call with Aratana Therapeutics (Nasdaq ETX) today at 8:00 am ET to discuss the recently announced global licensing agreement for Advaxis's ADXS-cHER2 for the treatment of osteosarcoma in dogs and three additional cancer immunotherapy products for the treatment of three other types of cancer.

Aratana and Advaxis Enter Exclusive Global Licensing Agreement
PR Newswire - Wed Mar 19, 7:01PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, and Advaxis, Inc. (NASDAQ: ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced a global licensing agreement for Advaxis' ADXS-cHER2 for the treatment of osteosarcoma in dogs and three additional cancer immunotherapy products for the treatment of three other types of cancer. Each of the four licensed products is based on Advaxis' platform immunotherapy technology, which Advaxis is developing for the treatment of human cancers on a global basis. Under the agreement, Aratana will have exclusive rights to develop and commercialize the licensed immunotherapies for pet health applications, and will focus initially on developing ADXS-cHER2 for osteosarcoma.

Advaxis Receives Patent in Japan for ADXS-HPV for the Treatment of Cervical Cancer
GlobeNewswire - Tue Mar 18, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced that it has been issued a significant patent from the Japan Patent Office, entitled, "Compositions and Methods for Enhancing Immunogenicity of Antigens". The claims of the patent (patent number 5479918) cover the use of ADXS-HPV for the treatment of late-stage cervical cancer with a term that extends to 2028.

Advaxis and UC San Francisco to Evaluate Cancer Immunotherapy Constructs in Prostate Cancer
GlobeNewswire - Mon Mar 17, 6:40AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that it has signed an agreement with the University of California, San Francisco (UCSF), under which Lawrence Fong, M.D., Professor in the Department of Medicine and principal investigator of the studies at UCSF, will evaluate several new immunotherapy constructs, in addition to ADXS-PSA, each built on the Advaxis proprietary technology. Data generated from this agreement will demonstrate the combination of the unique Advaxis immunotherapy platform, which generates both tumor fighting T cells and reduces tumor protection inside the tumor microenvironment, with targets that have already been shown to be important in effective immunotherapies for prostate cancer.

Advaxis to Present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum
GlobeNewswire - Thu Mar 13, 8:01AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced that the company will present at the 2 Annual Sachs Cancer Bio Partnering & Investment Forum on Wednesday, March 19 at the New York Academy of Sciences. Robert G. Petit, Ph.D., Chief Scientific Officer of Advaxis, will serve on an expert panel titled "Immunotherapies and Cancer Vaccines" at 11:45am and Daniel J. O'Connor, Chief Executive Officer of Advaxis, will present an update on the Company at 1:30pm.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

XKIG Bolsters Northwest with Jensen's Acquisition

Updated Category News Views 13

Stepping Up the Game in the Pacific Northwest Well, here we see another classic example of a shrewd move in the infrastructure sector. XKIG, a name known to those who keep an eye on critical infrastructure services for utilities, has decided to widen its footprint with a strategic grab of Jensen's Tree Service, Inc. They’re setting up shop even deeper in the Pacific...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 152

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
ISC2 Launches AI Security Academy for Cyber Pros

Updated Category News Views 77

AI-Driven Threats Demand Expert Attention Every corner of the tech world has been blabbering about AI, but when it comes to cybersecurity, it's a whole different beast entirely. ISC2—a nonprofit that I like to think of as the cyber wizards’ guild—just threw a lifeline to cybersecurity folks who are swimming in the deep end of AI. With their shiny new AI Security...

Continue Reading
Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 160

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
ICEYE Launches Gen5 SAR Satellite for Unrivaled Clarity

Updated Category News Views 92

Well, if you've been sleeping under a rock and missed the news, ICEYE just dropped another bombshell in the satellite biz. Gen5 is the name of the game, and it's claiming the spotlight for its razor-sharp imaging prowess. Now, we're talking about a satellite that supposedly snaps pictures with a resolution as fine as 11 cm. That's like spotting a flea on a dog's back from...

Continue Reading
NaLA Pushes for Stronger Lifeline Fraud Measures

Updated Category News Views 31

Here's the thing about the Lifeline program: it's meant to be a lifeline, not a loophole for the crafty and unscrupulous. The National Lifeline Association (NaLA) is slamming the table, demanding that the Senate Commerce Committee put some real muscle into preventing fraud. Why the Urgency on Lifeline Fraud? NaLA’s got its sights on a more robust defensive line against...

Continue Reading
Surgical Tooth Extraction: When It’s Necessary

Updated Category News Views 42

Unpacking the Complexities of Tooth Extraction Ever wonder why some tooth extractions are a stroll in the park while others dive straight into surgical territory? It's all about positioning, condition, and what's lurking underneath. Thanks to Dr. Yadira Cardona-Rohena of Hamilton Mill Oral & Facial Surgery, we’ve got the lowdown. The Need for Skilled Surgical Techniques...

Continue Reading
Visit W&H at the Greater New York Dental Meeting

Updated Category News Views 52

Why This Event Matters for Dental Professionals Stroll through any convention center halls and you can see the future unfolding right in front of you. The upcoming Greater New York Dental Meeting is no different, especially with W&H Group setting up shop. For any dental professionals out there, this is your chance to get your hands on some real-deal tech that might just...

Continue Reading
DarioHealth's New Research Tackles Healthcare Cost Estimation

Updated Category News Views 104

Unpacking Dario's Bold Surgical Strike at ISPOR Europe Alright, folks, DarioHealth is shaking up the stage with their new methodology that could very well carve a new path in how we size up digital healthcare savings. Presented at ISPOR Europe 2026, Dario's tactic bypasses the sluggish wait on medical claims data, instead offering an evidence-driven peek at potential...

Continue Reading
Alley Cat Allies Pushes for Humane Cat Conservation Bill

Updated Category News Views 22

Time to Rethink Conservation: Save the Cats If you’re tuned into the chatter buzzing around the Cayman Islands, you know the clocks are ticking for a decision that could change the approach to handling community cats. Alley Cat Allies is waving the flag, urging the Cayman Islands Parliament to pass a bill that abandons the archaic practice of culling cats by shooting...

Continue Reading

Top 5 Most Recently Viewed Articles

PriceSmart Achieves Strong First Quarter Results and Expansion Plans

Updated Category News Views 229

PriceSmart Reports Impressive Growth in First Quarter of Fiscal 2026 PriceSmart, Inc. (NASDAQ: PSMT), with a presence across multiple regions, has announced substantial financial results for the first quarter of fiscal 2026, highlighting their ongoing growth and expansion strategies. The recent quarter ended on November 30, 2025, and the figures reflect a robust upward...

Continue Reading
Discover the New Belleza Community with Model Homes in California

Updated Category News Views 400

Exciting New Community in California Belleza at Lakeview is thrilled to announce the opening of their model homes, marking a significant step forward in the development of a brand new community in California. This community, designed with precision and style, invites potential homeowners to explore two stunning model homes, set to open soon for tours. Homebuyers are in...

Continue Reading
Bullish Nasdaq Signals Strong Potential for Long Investments

Updated Category News Views 89

Understanding Nasdaq's Recent Performance Recent market movements have highlighted a robust resurgence for bullish traders as they confidently regain control of their positions. The gains witnessed were particularly notable as the market showed resilience in defending critical support levels. Nasdaq's Bullish Technical Indicators As we explore the Nasdaq index, it becomes...

Continue Reading
Zero Homes Expands Services for Energy-Efficient Solutions

Updated Category News Views 123

Zero Homes Launches Comprehensive Services Across Colorado Zero Homes, a pioneering startup focused on digital solutions for home electrification, has announced its comprehensive statewide services tailored for every homeowner in Colorado. With its innovative approach, Zero Homes aims to guide residents in tapping into the newly established Colorado Home Energy Rebate...

Continue Reading
United Community Bank Foundation Commits $350,000 for Relief Aid

Updated Category News Views 107

United Community Bank Foundation's Commitment to Relief Efforts In the wake of the severe devastation caused by Hurricane Helene in the southern regions, the United Community Bank Foundation has stepped forward with a significant pledge. They are dedicating a remarkable amount of $350,000 to support local nonprofits that are actively engaged in the recovery and assistance...

Continue Reading